Efficacy and Safety of Bimekizumab Without an Induction Regimen in Patients With Moderate‐to‐Severe Plaque Psoriasis: A Real‐World Clinical Practice Study
Authors:
- José Ángel Domínguez GarcíaJGJosé Ángel Domínguez García
- Jorge Alonso Suárez PérezJPJorge Alonso Suárez Pérez
- Pedro José Navarro GuillamónPGPedro José Navarro Guillamón
- Silvia Habicheyn HiarSHSilvia Habicheyn Hiar
- Rosa María Castillo MuñozRMRosa María Castillo Muñoz
- Enrique Herrera AcostaEAEnrique Herrera Acosta
Open Access
- 1 January 2026
- journal article
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 8672172
Abstract
Background: In clinical practice, some patients present with moderate baseline inflammatory burden (Psoriasis Area and Severity Index [PASI] 5–10), in whom the need for an induction phase with bimekizumab remains uncertain. The aim was to evaluate, under real‐world conditions, whether initiating treatment without an induction regimen allows comparable clinical responses in patients with lower baseline inflammatory burden. Methods: A prospective observational study was conducted including 65 adult patients with moderate‐to‐severe plaque psoriasis treated with bimekizumab with an induction regimen ( n = 39) or without induction ( n = 26) and followed for 24 weeks. The noninduction strategy was preferentially used in patients with lower baseline inflammatory activity according to clinical judgment. Clinical efficacy outcomes were analysed at baseline and Week 24, with PASI90 as the primary endpoint, and adverse events and treatment discontinuations were also recorded. Results: Baseline PASI was higher in the induction group (12.3 ± 4.2) than in the noninduction group (6.9 ± 2.5; p < 0.001). At Week 24, mean PASI was 0.70 ± 1.05 in the induction group and 0.40 ± 0.49 in the noninduction group. PASI90 response rates were 69% and 73%, respectively ( p = 0.79). The overall incidence of mucocutaneous candidiasis was 9.2% (6/65), occurring exclusively in the induction group (15.4% vs 0%; p = 0.03). Two patients required discontinuation. Conclusions: In patients with lower baseline inflammatory burden, a noninduction strategy achieved high clinical responses comparable to the standard induction regimen at 24 weeks. Lower drug exposure may be associated with a favourable safety profile in selected patients.Keywords
This publication has 25 references indexed in Scilit:
- Global Psoriasis Burden and Forecasts to 2050JAMA Dermatology, 2026
- Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective studyArchives of Dermatological Research, 2024
- Risk of fungal infection in patients with psoriasis receiving biologics: A retrospective single-center cohort studyJournal of the American Academy of Dermatology, 2024
- Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world settingArchives of Dermatological Research, 2024
- Biologics for PsoriasisDermatologic Clinics, 2024
- Bimekizumab Safety in Patients With Moderate to Severe Plaque PsoriasisJAMA Dermatology, 2022
- Bimekizumab versus Secukinumab in Plaque PsoriasisNew England Journal of Medicine, 2021
- PsoriasisThe Lancet, 2021
- Pathophysiology, Clinical Presentation, and Treatment of PsoriasisJAMA, 2020
- Guidelines of care for the management of psoriasis and psoriatic arthritisJournal of the American Academy of Dermatology, 2008